ALSO NOTED: Investors to pay $1.3 billion for Axcan; Smith & Nephew recalls knee implants;

> Canada's Axcan Pharma has agreed to a buyout by the private equity firm TPG Capital for $1.3 billion. Release

> Device maker Smith & Nephew is recalling some 600 knee implants that may contain too much iron; about 275 of the devices have already been implanted into patients. Report

> Germany's Merck KgaA won approval from the European Commission to sell a treatment kit for cyanide poisoning. Report

> Health Canada gave its blessing to Cangene's liquid formulation of a blood-disorder drug used in infants. Report

> The Chinese government announced that it intends to impose heavy punishments on makers of counterfeit drugs; in some cases, this may include the death penalty. Report

And Finally... A doctors' group wants to standardize and simplify prescription labels to make sure patients understand when and how to take their medicine. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.